A Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT)
Phase 1
Completed
- Conditions
- Multiple Myeloma
- Interventions
- Drug: JNJ-26866138 0.7 mg/m2Drug: JNJ-26866138 1.0 mg/m2Drug: JNJ-26866138 1.3 mg/m2Drug: MelphalanDrug: Prednisolone
- First Posted Date
- 2009-09-29
- Last Posted Date
- 2013-12-02
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 101
- Registration Number
- NCT00985959
An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease
Phase 3
Completed
- Conditions
- Alzheimer's Disease
- Interventions
- First Posted Date
- 2008-12-25
- Last Posted Date
- 2014-04-17
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 580
- Registration Number
- NCT00814801
Phase 2 Study of Tapentadol Prolonged Release in Cancer Pain Participants
- First Posted Date
- 2008-12-09
- Last Posted Date
- 2013-07-29
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 78
- Registration Number
- NCT00805142
A Study of JNJ-30979754 (Decitabine) in Patients With Myelodysplastic Syndrome
Phase 1
Completed
- Conditions
- Myelodysplastic Syndrome
- Interventions
- Drug: JNJ-30979754 15 mg/m2Drug: JNJ-30979754 20 mg/m2
- First Posted Date
- 2008-11-24
- Last Posted Date
- 2013-12-09
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 39
- Registration Number
- NCT00796003
An Efficacy and Safety Study of Fentanyl in Participants With Chronic Pain
- First Posted Date
- 2008-11-10
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 142
- Registration Number
- NCT00788372
A Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and Those With Febrile Neutropenia Suspected of Fungal Infection
Phase 3
Completed
- Conditions
- MycosesCandidiasisAspergillosisCryptococcosisBlastomycosisHistoplasmosisNeutropenia
- Interventions
- Drug: ITCZ Oral SolutionDrug: ITCZ-IV
- First Posted Date
- 2008-11-02
- Last Posted Date
- 2013-07-25
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 55
- Registration Number
- NCT00784368
A Safety and Efficacy Study of Golimumab (CNTO148) in Patients With Active Rheumatoid Arthritis (RA)
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: CNTO 148Drug: Placebo
- First Posted Date
- 2008-10-13
- Last Posted Date
- 2015-11-03
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 311
- Registration Number
- NCT00771251
A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients
Phase 1
Completed
- Conditions
- RefractoryMultiple MyelomaRelapse
- First Posted Date
- 2008-09-15
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 35
- Registration Number
- NCT00752518
An Exploratory Study of Tramadol Hydrochloride in Patients With Osteoarthritis of the Knee or Low Back Pain
Phase 2
Completed
- Conditions
- OsteoarthritisLow Back Pain
- First Posted Date
- 2008-09-15
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 119
- Registration Number
- NCT00752661
An Efficacy and Safety Study of Acetaminophen Plus Tramadol Hydrochloride (JNS013) in Participants With Chronic Pain
Phase 3
Completed
- Conditions
- Pain
- Interventions
- First Posted Date
- 2008-08-18
- Last Posted Date
- 2013-09-26
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 321
- Registration Number
- NCT00736853
© Copyright 2025. All Rights Reserved by MedPath